CHDI
Listed here are over 950 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans
Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE
Huntingtin interacting proteins are genetic modifiers of neurodegeneration
Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP
The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes
Brain Res Bull
April 30, 2007
72 (2-3) :83-97
72 (2-3) :83-97
PMID: 17352931
Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, Oakes D, Shoulson I, Penziner E, Paulsen JS, Predict-HD Investigators of the Huntington Study Group
Verbal episodic memory declines prior to diagnosis in Huntington`s disease
Varma H, Voisine C, DeMarco CT, Cattaneo E, Lo DC, Hart AC, Stockwell BR
Selective inhibitors of death in mutant huntingtin cells
Beglinger LJ, Langbehn DR, Duff K, Stierman L, Black DW, Nehl C, Anderson K, Penziner E, Paulsen JS, Huntington Study Group Investigators
Probability of obsessive and compulsive symptoms in Huntington`s disease
Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration
Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Cao C, Temel Y, Blokland A, Ozen H, Steinbusch HW, Vlamings R, Nguyen HP, von Hörsten S, Schmitz C, Visser-Vandewalle V
Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel
Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC
Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice
Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR
Body weight is modulated by levels of full-length huntingtin
Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group
Preparing for preventive clinical trials: the Predict-HD study
Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery
Paulsen JS, Zimbelman JL, Hinton SC, Langbehn DR, Leveroni CL, Benjamin ML, Reynolds NC, Rao SM
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease
AJNR Am J Neuroradiol
November 2, 2004
25 (10) :1715-21
25 (10) :1715-21
PMID: 15569736